Icon plc (ICLR) “Hold” Rating Reaffirmed by Analysts at Mizuho Securities; With $114.0 Target; Walker & Dunlop (WD) SI Increased By 3.21%

February 15, 2018 - By Russell Anderson

Walker & Dunlop Incorporated (NYSE:WD) had an increase of 3.21% in short interest. WD’s SI was 819,200 shares in February as released by FINRA. Its up 3.21% from 793,700 shares previously. With 258,800 avg volume, 3 days are for Walker & Dunlop Incorporated (NYSE:WD)’s short sellers to cover WD’s short positions. The SI to Walker & Dunlop Incorporated’s float is 2.93%. The stock increased 0.93% or $0.47 during the last trading session, reaching $51.04. About 66,511 shares traded. Walker & Dunlop, Inc. (NYSE:WD) has risen 103.91% since February 15, 2017 and is uptrending. It has outperformed by 87.21% the S&P500.

Among 12 analysts covering Icon plc (NASDAQ:ICLR), 8 have Buy rating, 1 Sell and 3 Hold. Therefore 67% are positive. Icon plc has $145.0 highest and $77 lowest target. $119.27’s average target is 4.62% above currents $114 stock price. Icon plc had 35 analyst reports since July 29, 2015 according to SRatingsIntel. As per Friday, December 16, the company rating was downgraded by SunTrust. Robert W. Baird maintained the stock with “Buy” rating in Thursday, August 31 report. On Thursday, June 8 the stock rating was maintained by Robert W. Baird with “Buy”. The stock has “Buy” rating by Jefferies on Monday, September 11. The firm has “Buy” rating by Goldman Sachs given on Friday, December 16. The firm has “Hold” rating by Suntrust Robinson given on Friday, December 16. The company was maintained on Thursday, October 26 by Robert W. Baird. SunTrust maintained it with “Buy” rating and $138.0 target in Monday, October 30 report. The stock of ICON Public Limited Company (NASDAQ:ICLR) has “Buy” rating given on Wednesday, January 10 by KeyBanc Capital Markets. KeyBanc Capital Markets maintained it with “Buy” rating and $115.0 target in Monday, October 16 report.

Among 9 analysts covering Walker & Dunlop (NYSE:WD), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Walker & Dunlop had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Walker & Dunlop, Inc. (NYSE:WD) has “Hold” rating given on Wednesday, June 7 by Keefe Bruyette & Woods. Keefe Bruyette & Woods downgraded the stock to “Market Perform” rating in Thursday, November 5 report. On Thursday, October 6 the stock rating was initiated by Wedbush with “Neutral”. Keefe Bruyette & Woods maintained it with “Hold” rating and $56.0 target in Thursday, December 21 report. The firm has “Hold” rating given on Friday, April 7 by Wood. As per Monday, August 17, the company rating was maintained by JP Morgan. The rating was maintained by Keefe Bruyette & Woods on Wednesday, February 7 with “Buy”. The stock of Walker & Dunlop, Inc. (NYSE:WD) earned “Outperform” rating by JMP Securities on Thursday, August 3. Keefe Bruyette & Woods upgraded the shares of WD in report on Friday, January 5 to “Buy” rating. The stock of Walker & Dunlop, Inc. (NYSE:WD) earned “Neutral” rating by Compass Point on Thursday, August 6.

Since December 18, 2017, it had 0 buys, and 6 selling transactions for $6.55 million activity. $937,008 worth of Walker & Dunlop, Inc. (NYSE:WD) was sold by Lucas Richard M on Friday, January 5. 1,000 shares valued at $46,544 were sold by Warner Richard C on Wednesday, January 10. $1.85M worth of Walker & Dunlop, Inc. (NYSE:WD) was sold by Walker William M on Monday, December 18.

Walker & Dunlop, Inc., through its subsidiaries, originates, sells, and services a range of multifamily and other commercial real estate financing products for owners and developers of real estate in the United States. The company has market cap of $1.59 billion. The firm offers a range of commercial real estate finance products, including first mortgage, second trust, construction, mezzanine, and bridge/interim loans, as well as supplemental financings through the programs of the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, the Government National Mortgage Association, and the Federal Housing Administration. It has a 11.05 P/E ratio. It also provides multifamily finance for multifamily, manufactured housing communities, student housing, affordable, and housing properties under the Fannie Mae DUS program; and FHA finance, such as construction and permanent loans to developers and owners of multifamily housing, affordable housing, senior housing, and healthcare facilities.

Investors sentiment decreased to 1.27 in 2017 Q3. Its down 0.16, from 1.43 in 2017Q2. It turned negative, as 24 investors sold Walker & Dunlop, Inc. shares while 54 reduced holdings. 42 funds opened positions while 57 raised stakes. 24.00 million shares or 0.06% less from 24.01 million shares in 2017Q2 were reported. Louisiana State Employees Retirement Systems holds 0.03% or 11,500 shares in its portfolio. Savings Bank Of New York Mellon Corporation owns 394,596 shares. Matarin Management Limited Liability has invested 1.16% of its portfolio in Walker & Dunlop, Inc. (NYSE:WD). Riverhead Cap Management Ltd Llc accumulated 0.01% or 3,253 shares. Pub Sector Pension Invest Board invested 0% in Walker & Dunlop, Inc. (NYSE:WD). Mason Street Advisors has invested 0.01% in Walker & Dunlop, Inc. (NYSE:WD). Arrowstreet Partnership reported 80,594 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Walker & Dunlop, Inc. (NYSE:WD) for 883 shares. Ftb Advisors Inc holds 187 shares or 0% of its portfolio. Pinebridge Lp reported 18,113 shares. Tci Wealth Advisors owns 0% invested in Walker & Dunlop, Inc. (NYSE:WD) for 29 shares. Symphony Asset Ltd Llc reported 0.11% stake. National Bank Of America Corporation De invested 0% in Walker & Dunlop, Inc. (NYSE:WD). State Of Tennessee Treasury Department reported 24,779 shares. Eulav Asset invested in 0.03% or 11,800 shares.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company has market cap of $6.17 billion. The firm specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It has a 22.08 P/E ratio. The Company’s clinical development services comprise product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>